ArticleThe Pan African medical journal2025
Mpox outbreak in Abia State, Nigeria, 2024: implications for varicella zoster virus coinfection among children.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mpox remains a significant public health concern in Africa with a notable increase in cases and outbreaks in several countries. Despite the efforts of surveillance and other specific interventions, Nigeria has been reporting ongoing cases since its re-emergence in 2017. We conducted an epidemiologic description of the 2024 Mpox outbreak in Abia State to understand the drivers and inform its control strategies. Methods: we investigated the cases and conducted a descriptive study of suspected cases of Mpox line listed in 2024. Data were collected with a standardized case investigation form. An active case search was conducted in affected communities, and a review of hospital records was done. Samples were collected and tested at the National Reference Laboratory for confirmation. The data was downloaded from SORMAS, cleaned, and analysed using SPSS. Frequencies, proportions, and attack rates were generated. Results: sixty-one suspected Mpox cases were line listed and 10 (16.4%) were laboratory-confirmed, with 6(60%) out of the confirmed cases having varicella zoster virus (VZV) coinfection. Among the confirmed cases, males constituted 60% (6/10), and the median age was 9.5 years (IQR: 3 - 27 years). The predominant age group was 0 - 15 years, 7 (70%). Out of the 12 reporting LGAs, confirmed cases were dominant in 5 LGAs. The commonest symptoms were fever (90%) and itchy vesiculopustular rash (90%). The most common symptom was fever (30%). Among all confirmed cases with rashes (90%), skin lesions were mostly on the face, legs, arms, and genitals. Ukwa East LGA had the highest attack rate (3/100,000 population). Conclusion: the confirmed cases were mostly children with a high prevalence of VZV coinfection, and males were mostly affected. We recommended targeted public health awareness campaigns to the demographic groups mostly affected and emphasized enhanced surveillance and early diagnosis to minimize complications from Mpox/VZV coinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.